Journal: Materials Today Bio

Article Title: A photodynamically activated nanoplatform relieves glucose-driven immunosuppression to potentiate STING immunotherapy in triple-negative breast cancer

doi: 10.1016/j.mtbio.2026.103071

Figure Lengend Snippet: Characterization of DI/Ce6 and DI/Ce6@STF. (A, B) Representative electron microscopy images of DI/Ce6 and DI/Ce6@STF, respectively (scale bar: 100 nm); (C) Zeta potential of DI/Ce6 and DI/Ce6@STF; (D, E) Hydrodynamic particle size distributions of DI/Ce6 and DI/Ce6@STF measured by dynamic light scattering; (F) Particle size stability of DI/Ce6 and DI/Ce6@STF in PBS over 7 days; (G, H) Release Curves of DIABZI and STF-31 in DI/Ce6@STF; (I) Comparison of HPLC chromatograms for DI/Ce6@STF nanoparticles and free drug.

Article Snippet: STF-31 (HY-18728), DIABZI (HY-112921A) and Ce6(HY-13594) were all purchased from MedChemExpress (Shanghai, China).

Techniques: Electron Microscopy, Zeta Potential Analyzer, Comparison

Journal: Cancer Research

Article Title: Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression

doi: 10.1158/0008-5472.CAN-25-3092

Figure Lengend Snippet: IL22 upregulates PD-L1 expression in gastric cancer cells through the UPR IRE1α–XBP1 axis. A, mIF images show the alterations of PD-L1 + tumor cells (purple), CD4 + (green), and CD8 + (red) T cells in orthotopic gastric cancer tumors from control and Abhd16a -knockdown mice following IL22 treatment. Scale bar, 50 μm. B, KEGG pathway enrichment analysis of RNA-seq data of gastric cancer tissues with or without IL22 treatment. C, RT-PCR was used to assess the mRNA expression of key downstream molecules of the UPR branches ( XBP1 , ATF4 , ATF6 ) in control and IL22RA1 -knockdown gastric cancer cells. D, Western blotting analysis of PD-L1 and XBP1s levels in control and IL22RA1 -knockdown MGC-803 cells treated with IL22 (100 μg/L). E, Western blotting detection of PD-L1 and XBP1s levels in XBP1- knockdown MGC-803 cells treated with IL22 and MGC-803 cells treated with IL22 or XBP1s inhibitor (STF083010, 30 μmol/L) in combination with IL22. F, The binding sequence of XBP1 on the CD274 promoter. G and H, ChIP ( G ) and luciferase reporter assay ( H ) showing the transcriptional regulation of CD274 by XBP1s under IL22 stimulation. I, Orthotopic gastric cancer mouse models ( n = 5 per group) were injected with anti-IL22 (200 μg per mouse), anti-CD90.2 antibody (150 μg per mouse), anti-CD90.2 antibody in combination with IL22 (500 ng per mouse), or anti-CD90.2 antibody in combination with XBP1s inhibitors (STF083010, 30 mg/kg) and IL22 for 2 weeks. IHC analysis was used to show IL22, XBP1s, and PD-L1 levels in gastric cancer tissues. Scale bar, 200 μm. J, Tumor volume of orthotopic gastric cancer models under treatments the same as in I . *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, nonsignificant.

Article Snippet: For immunotherapy, anti-mouse PD-L1 antibody (100 μg/mouse, TargetMol, T78270 ), GPR34 inhibitor (GPR34 receptor antagonist 2, 20 mg/kg, MERYER, 907952), and XBP1s inhibitor (STF-083010, 30 mg/kg, MedChemExpress, HY-15845) were intraperitoneally injected once every 3 days, and ACh receptor inhibitor (darifenacin, 2.5 mg/kg, MedChemExpress, HY–A0033) was intraperitoneally injected every day after tumor formation.

Techniques: Expressing, Control, Knockdown, RNA Sequencing, Reverse Transcription Polymerase Chain Reaction, Western Blot, Binding Assay, Sequencing, Luciferase, Reporter Assay, Injection

Journal: Cancer Research

Article Title: Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression

doi: 10.1158/0008-5472.CAN-25-3092

Figure Lengend Snippet: Combination therapy enhances the anti–PD-L1 immunotherapeutic effect in gastric cancer. A and B, After tumor formation, the orthotopic gastric cancer mice ( n = 5 per group) were treated with anti–PD-L1 (100 μg per mouse), GPR34 inhibitor (20 mg/kg), or XBP1s inhibitor (30 mg/kg) every 3 days or ACh inhibitor (2.5 mg/kg) daily. Combinations of anti–PD-L1 with each inhibitor followed the every 3-day dosing schedule for a total duration of 2 weeks via i.p. injection. Living images were used to monitor tumor progression at 5-day intervals from the time of drug administration ( A ); IHC and mIF were performed to detect PD-L1 and XBP1s levels and proportions of CD4 + (green) and CD8 + (red) T cells in gastric cancer tissues at the end of treatments ( B ). Scale bars, 1.000e+5 –∼ 5.000e + 5 p/s/cm 2 /sr for living images; 200 μm for IHC; 50 μm for immunofluorescence. C and D, Representative images ( C ) and tumor volume ( D ) of subcutaneous tumors. The administration protocol for the mice was consistent with the description provided in A and B . **, P < 0.01; ***, P < 0.001.

Article Snippet: For immunotherapy, anti-mouse PD-L1 antibody (100 μg/mouse, TargetMol, T78270 ), GPR34 inhibitor (GPR34 receptor antagonist 2, 20 mg/kg, MERYER, 907952), and XBP1s inhibitor (STF-083010, 30 mg/kg, MedChemExpress, HY-15845) were intraperitoneally injected once every 3 days, and ACh receptor inhibitor (darifenacin, 2.5 mg/kg, MedChemExpress, HY–A0033) was intraperitoneally injected every day after tumor formation.

Techniques: Injection, Immunofluorescence